Individualized Investigational Treatments :
HB 1333 creates a new Florida statute authorizing the use of “individualized investigational treatments” for certain patients with life-threatening or severely debilitating illnesses. The bill is aimed at highly personalized drugs, biological products, or devices made specifically for one patient based on that patient’s genetic profile, including examples such as individualized gene therapies, antisense oligonucleotides, and neoantigen vaccines. To qualify, a patient must have exhausted approved FDA treatment options, receive a treating physician’s recommendation, and provide detailed written informed consent acknowledging the experimental nature of the treatment and its risks.
The bill allows eligible facilities operating under federal human-subjects protections, and manufacturers operating within those facilities, to provide these treatments and to charge patients for manufacturing costs if they choose. It also permits health plans, third-party administrators, and governmental agencies to cover the costs, but does not require them to do so or expand existing insurance coverage mandates. The bill further states that if a patient dies, heirs are not liable for outstanding debt related to the treatment or resulting insurance issues, and it bars the bill from creating a private cause of action against compliant manufacturers or providers acting in good faith.
HB 1333 would add s. 381.992 to the Florida Statutes and create a legal framework for access to individualized investigational therapies in Florida. It would limit professional discipline and Medicare-certification consequences for providers who recommend such treatments, prohibit state officials from blocking patient access, and clarify that participation does not expand mandatory insurance coverage or require hospitals, insurers, or government agencies to pay for treatment absent another legal obligation. The bill would also provide liability protections for compliant actors and shield heirs from certain post-death treatment debts.
The bill appears to have been framed as a patient-access and medical-innovation measure, with its structure emphasizing physician judgment, informed consent, and protections for providers and patients seeking last-resort options. However, there is no recorded committee transcript or vote history in the provided materials, and the bill died in the Health Professions & Programs Subcommittee. That outcome suggests it did not advance, but the available record does not show direct debate or a formal vote count to indicate the level of support or opposition.
The main points of potential contention are the bill’s treatment of experimental therapies, cost responsibility, and limits on regulatory oversight. Supporters would likely emphasize expanded access for terminally ill or severely debilitated patients and protection for physicians recommending individualized treatments. Opponents or skeptics could focus on patient safety, the uncertain efficacy of highly personalized investigational products, the possibility of financial burden on patients and families, and the bill’s restrictions on licensing boards, Medicare-related actions, and state interference. The bill also carefully avoids mandating coverage, which may reflect concern about shifting costs to insurers, public programs, or providers.